Cargando…

Case report: Sandwich therapy of CAR-T combined with ASCT: Sequential CAR-T cell therapy with ASCT after remission with CAR-T therapy caused long-term survival in a patient with relapsed/refractory Burkitt’s lymphoma with TP53 mutations

Burkitt’s lymphoma (BL) with TP53 mutation often has poor outcome after standard chemoimmunotherapy. Adoptive chimeric antigen receptor (CAR)-T cell therapy may be a new paradigm for treating refractory/relapsed (r/r) BL, but its therapeutic effects remain inconclusive. Here, we report a patient wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Qi, Zhu, Xiaojian, Liu, Bo, Zhang, Yicheng, Xiao, Yi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10063779/
https://www.ncbi.nlm.nih.gov/pubmed/37006273
http://dx.doi.org/10.3389/fimmu.2023.1127868
_version_ 1785017766499057664
author Zhang, Qi
Zhu, Xiaojian
Liu, Bo
Zhang, Yicheng
Xiao, Yi
author_facet Zhang, Qi
Zhu, Xiaojian
Liu, Bo
Zhang, Yicheng
Xiao, Yi
author_sort Zhang, Qi
collection PubMed
description Burkitt’s lymphoma (BL) with TP53 mutation often has poor outcome after standard chemoimmunotherapy. Adoptive chimeric antigen receptor (CAR)-T cell therapy may be a new paradigm for treating refractory/relapsed (r/r) BL, but its therapeutic effects remain inconclusive. Here, we report a patient with r/r BL who failed to achieve complete remission (CR) and progressed rapidly after multiple protocol chemotherapy. The patient achieved CR with CAR19 and CAR22 T-cell cocktail therapy and obtained long-term disease-free survival after autologous hematopoietic stem cells (ASCT) and subsequential CAR19 and CAR22 T-cell cocktail therapy. The clinical evolution and genetic features of this case may provide some guidance for CAR-T therapy in overcoming relapses associated with TP53 gene mutations.
format Online
Article
Text
id pubmed-10063779
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-100637792023-04-01 Case report: Sandwich therapy of CAR-T combined with ASCT: Sequential CAR-T cell therapy with ASCT after remission with CAR-T therapy caused long-term survival in a patient with relapsed/refractory Burkitt’s lymphoma with TP53 mutations Zhang, Qi Zhu, Xiaojian Liu, Bo Zhang, Yicheng Xiao, Yi Front Immunol Immunology Burkitt’s lymphoma (BL) with TP53 mutation often has poor outcome after standard chemoimmunotherapy. Adoptive chimeric antigen receptor (CAR)-T cell therapy may be a new paradigm for treating refractory/relapsed (r/r) BL, but its therapeutic effects remain inconclusive. Here, we report a patient with r/r BL who failed to achieve complete remission (CR) and progressed rapidly after multiple protocol chemotherapy. The patient achieved CR with CAR19 and CAR22 T-cell cocktail therapy and obtained long-term disease-free survival after autologous hematopoietic stem cells (ASCT) and subsequential CAR19 and CAR22 T-cell cocktail therapy. The clinical evolution and genetic features of this case may provide some guidance for CAR-T therapy in overcoming relapses associated with TP53 gene mutations. Frontiers Media S.A. 2023-03-17 /pmc/articles/PMC10063779/ /pubmed/37006273 http://dx.doi.org/10.3389/fimmu.2023.1127868 Text en Copyright © 2023 Zhang, Zhu, Liu, Zhang and Xiao https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Zhang, Qi
Zhu, Xiaojian
Liu, Bo
Zhang, Yicheng
Xiao, Yi
Case report: Sandwich therapy of CAR-T combined with ASCT: Sequential CAR-T cell therapy with ASCT after remission with CAR-T therapy caused long-term survival in a patient with relapsed/refractory Burkitt’s lymphoma with TP53 mutations
title Case report: Sandwich therapy of CAR-T combined with ASCT: Sequential CAR-T cell therapy with ASCT after remission with CAR-T therapy caused long-term survival in a patient with relapsed/refractory Burkitt’s lymphoma with TP53 mutations
title_full Case report: Sandwich therapy of CAR-T combined with ASCT: Sequential CAR-T cell therapy with ASCT after remission with CAR-T therapy caused long-term survival in a patient with relapsed/refractory Burkitt’s lymphoma with TP53 mutations
title_fullStr Case report: Sandwich therapy of CAR-T combined with ASCT: Sequential CAR-T cell therapy with ASCT after remission with CAR-T therapy caused long-term survival in a patient with relapsed/refractory Burkitt’s lymphoma with TP53 mutations
title_full_unstemmed Case report: Sandwich therapy of CAR-T combined with ASCT: Sequential CAR-T cell therapy with ASCT after remission with CAR-T therapy caused long-term survival in a patient with relapsed/refractory Burkitt’s lymphoma with TP53 mutations
title_short Case report: Sandwich therapy of CAR-T combined with ASCT: Sequential CAR-T cell therapy with ASCT after remission with CAR-T therapy caused long-term survival in a patient with relapsed/refractory Burkitt’s lymphoma with TP53 mutations
title_sort case report: sandwich therapy of car-t combined with asct: sequential car-t cell therapy with asct after remission with car-t therapy caused long-term survival in a patient with relapsed/refractory burkitt’s lymphoma with tp53 mutations
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10063779/
https://www.ncbi.nlm.nih.gov/pubmed/37006273
http://dx.doi.org/10.3389/fimmu.2023.1127868
work_keys_str_mv AT zhangqi casereportsandwichtherapyofcartcombinedwithasctsequentialcartcelltherapywithasctafterremissionwithcarttherapycausedlongtermsurvivalinapatientwithrelapsedrefractoryburkittslymphomawithtp53mutations
AT zhuxiaojian casereportsandwichtherapyofcartcombinedwithasctsequentialcartcelltherapywithasctafterremissionwithcarttherapycausedlongtermsurvivalinapatientwithrelapsedrefractoryburkittslymphomawithtp53mutations
AT liubo casereportsandwichtherapyofcartcombinedwithasctsequentialcartcelltherapywithasctafterremissionwithcarttherapycausedlongtermsurvivalinapatientwithrelapsedrefractoryburkittslymphomawithtp53mutations
AT zhangyicheng casereportsandwichtherapyofcartcombinedwithasctsequentialcartcelltherapywithasctafterremissionwithcarttherapycausedlongtermsurvivalinapatientwithrelapsedrefractoryburkittslymphomawithtp53mutations
AT xiaoyi casereportsandwichtherapyofcartcombinedwithasctsequentialcartcelltherapywithasctafterremissionwithcarttherapycausedlongtermsurvivalinapatientwithrelapsedrefractoryburkittslymphomawithtp53mutations